The era of “business as usual” between the pharmaceutical industry and the UK is over. In the face of a deteriorating market, major drugmakers are no longer willing to quietly accept the status quo and are instead demanding radical change to the way the country prices and pays for new medicines.
This shift is marked by an unprecedented level of public criticism and coordinated action. The labeling of the UK as a “terrible place” by a Sanofi executive, coupled with the dramatic cancellation of MSD’s £1bn R&D hub, signals a new, more confrontational approach from an industry that feels its concerns have been ignored for too long.
The demand is for a complete overhaul, not minor tweaks. The industry wants a “proper plan” that fundamentally resets the UK’s commercial framework. This includes a multi-year commitment to increase spending, a modernization of the 25-year-old NICE assessment process, and a drastic cut to the revenue clawback rate.
The government is now faced with a choice: either engage in the radical reform the industry is demanding or preside over the continued decline of a key economic sector. The message from pharma is clear: the old way of doing things is no longer an option.
